A major goal of the biomedical research enterprise is to have a positive impact on patients and their caregivers.  Laboratories in the Department of Genetics and Genome Sciences are committed to advancing their ground breaking discoveries forward to clinical testing.  Our therapeutic development efforts are enhanced by a state-of-the-art Small Molecule Drug Development Core Facility managed by Yuriy Federov and directed by Drew Adams.

The research groups led by Paul Tesar and Drew Adams are using high throughput chemical screening to identify and develop regenerative therapeutics for myelin disorders such as multiple sclerosis.  Peter Scacheri and John Wang’s laboratories are developing new therapies for osteosarcoma and colon cancer.